News

Eli Lilly and Company announced that its investigational oral GLP-1 receptor agonist, orforglipron, delivered significant weight loss and blood sugar control in a Phase 3 clinical trial…
Read More...

Kite, a Gilead Company, announced it will acquire Interius BioTherapeutics, a privately held biotech firm pioneering in vivo CAR therapies, in a $350 million deal aimed at advancing…
Read More...

Johnson & Johnson has announced a major expansion of its U.S. manufacturing capabilities with a $2 billion, 10-year investment in a new 160,000+ square foot facility at FUJIFILM’s…
Read More...

Andelyn Biosciences, Inc., a leading contract development and manufacturing organization (CDMO) specializing in cell and gene therapies, has announced a new partnership with Amplo…
Read More...

Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema…
Read More...

Keros Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to KER-065 for the treatment of Duchenne muscular dystrophy (DMD), a…
Read More...

Jazz Pharmaceuticals plc and Saniona have entered into a global licensing agreement granting Jazz exclusive worldwide rights to develop and commercialize SAN2355, a subtype-selective…
Read More...

Crinetics Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to atumelnant, its once-daily oral ACTH receptor…
Read More...

Boehringer Ingelheim has signed a contract development and manufacturing agreement with AnGes Inc. to produce the drug substance for AnGes' investigational Hepatocyte Growth Factor…
Read More...

PTC Therapeutics, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for vatiquinone, a…
Read More...

Santen Pharmaceutical Co., Ltd. has announced a new licensing agreement with Chinese biopharmaceutical company RemeGen Co., Ltd. to exclusively develop, manufacture, and commercialize…
Read More...

Madrigal Pharmaceuticals, Inc. has received conditional marketing authorization from the European Commission (EC) for Rezdiffra (resmetirom), making it the first and only approved…
Read More...

SpringWorks Therapeutics, part of Merck KGaA, Darmstadt, Germany, announced that the European Commission (EC) has granted marketing authorization for OGSIVEO (nirogacestat), an oral…
Read More...

SystImmune Inc. and Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan…
Read More...

Boehringer Ingelheim and Palatin Technologies, Inc. have announced a global research collaboration and licensing agreement to develop a novel treatment targeting retinal diseases. This…
Read More...

Precigen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted full approval to PAPZIMEOS (zopapogene imadenovec-drba), the first and only FDA-approved treatment…
Read More...

Kexing Biopharm has announced a strategic partnership with IQVIA, a global leader in clinical research and healthcare intelligence, to accelerate the international development and…
Read More...

Viatris Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its Iron Sucrose Injection, USP, the first generic version of Venofer Injection. This intravenous…
Read More...

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to HERNEXEOS (zongertinib tablets), Boehringer Ingelheim’s new oral targeted therapy for adults with…
Read More...

GSK announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for gepotidacin, an oral antibiotic, for the treatment of…
Read More...